Lutetium-177-labeled radiopharmaceuticals aiming somatostatin receptors in metastatic neuroendocrine tumors (177Lu-DOTATATE, lutathera®) or PSMA in castration-resistant metastatic prostate cancer (177Lu-PSMA-617, pluvicto®) are now new standards of care 2, 3, and many other tumor-targeting radiopharmaceuticals are being developed 1. Here, FOLH1 is linked to metastatic prostate carcinoma.